Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1978 1
1979 1
1980 1
1984 3
1985 4
1986 1
1987 4
1988 3
1990 2
1991 1
1992 1
1993 3
1994 2
1995 2
1996 3
1997 3
1998 3
1999 1
2000 1
2001 3
2002 4
2003 5
2004 8
2005 15
2006 18
2007 16
2008 20
2009 14
2010 17
2011 20
2012 15
2013 18
2014 26
2015 24
2016 28
2017 32
2018 32
2019 32
2020 38
2021 29
Text availability
Article attribute
Article type
Publication date

Search Results

402 results
Results by year
Filters applied: . Clear all
Page 1
Physical activity and obesity in children.
Hills AP, Andersen LB, Byrne NM. Hills AP, et al. Among authors: byrne nm. Br J Sports Med. 2011 Sep;45(11):866-70. doi: 10.1136/bjsports-2011-090199. Br J Sports Med. 2011. PMID: 21836171 Free article. Review.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Among authors: byrne n. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Among authors: byrne n. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Physical Activity and Health: "What is Old is New Again".
Hills AP, Street SJ, Byrne NM. Hills AP, et al. Among authors: byrne nm. Adv Food Nutr Res. 2015;75:77-95. doi: 10.1016/bs.afnr.2015.06.001. Epub 2015 Aug 7. Adv Food Nutr Res. 2015. PMID: 26319905 Review.
Direct-to-consumer genetic testing for predicting sports performance and talent identification: Consensus statement.
Webborn N, Williams A, McNamee M, Bouchard C, Pitsiladis Y, Ahmetov I, Ashley E, Byrne N, Camporesi S, Collins M, Dijkstra P, Eynon N, Fuku N, Garton FC, Hoppe N, Holm S, Kaye J, Klissouras V, Lucia A, Maase K, Moran C, North KN, Pigozzi F, Wang G. Webborn N, et al. Among authors: byrne n. Br J Sports Med. 2015 Dec;49(23):1486-91. doi: 10.1136/bjsports-2015-095343. Br J Sports Med. 2015. PMID: 26582191 Free PMC article.
Quantification of lean bodyweight.
Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Janmahasatian S, et al. Among authors: byrne nm. Clin Pharmacokinet. 2005;44(10):1051-65. doi: 10.2165/00003088-200544100-00004. Clin Pharmacokinet. 2005. PMID: 16176118
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB. Byrne NJ, et al. Circ Heart Fail. 2020 Jan;13(1):e006277. doi: 10.1161/CIRCHEARTFAILURE.119.006277. Epub 2020 Jan 20. Circ Heart Fail. 2020. PMID: 31957470
402 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page